CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

gedatolisib

Small moleculeexperimental

Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Celcuity, Inc. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. — Wikipedia

Clinical trial activity

21 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
14
Phase 2
11
Phase 3
2
Phase 4
0

Earliest trial started Jan 1, 2010 (NCT00940498)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1
Mol. weight
615.74 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
  • gedatolisib
  • gedatolisib
  • gedatolisib
  • gedatolisib
  • pf-05212384
  • pf-05212384
  • pf-05212384
  • pf-05212384
  • pki587
  • pki 587
  • pki-587
  • pki-587
  • pki-587

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06757634Phase 3Jun 30, 2025Celcuity
NCT06190899Phase 1/Phase 2 (Phase 2)Jan 1, 2024Celcuity
NCT05501886Phase 3Sep 30, 2022Celcuity
NCT03911973Phase 1/Phase 2 (Phase 2)May 31, 2019Big Ten Cancer Research Consortium, Pfizer, University of Wisconsin
NCT03698383Phase 2Oct 31, 2018Seoul National University
NCT03400254Phase 1/Phase 2 (Phase 2)Feb 28, 2018Translational Breast Cancer Research Consortium (TBCRC), University of Pennsylvania
NCT03243331Phase 1Jan 19, 2018Indiana University
NCT02920450Phase 1/Phase 2 (Phase 2)Jun 30, 2017Pfizer, University of Florida
NCT03065062Phase 1Feb 28, 2017Harvard University, Pfizer
NCT02684032Phase 1Jun 14, 2016Pfizer
NCT02626507Phase 1Jan 1, 2016Eastchester Center for Cancer Care
NCT02438761Phase 2Aug 31, 2015Curie Institute, Fondation ARC, National Cancer Institute, France
NCT02142920Phase 1Jul 1, 2014Pfizer
NCT02069158Phase 1Apr 1, 2014Oncology Institute of Southern Switzerland, Ospedale S. Giovanni Bellinzona
NCT01937715Phase 1/Phase 2 (Phase 2)Feb 1, 2014Pfizer
NCT01925274Phase 2Nov 1, 2013Pfizer
NCT01920061Phase 1Sep 10, 2013Pfizer
NCT01420081Phase 2Jan 1, 2012Pfizer
NCT01347866Phase 1Oct 1, 2011Pfizer
NCT00940498Phase 1Jan 1, 2010Pfizer
Showing 20 of 21 trials
Page 1 / 2

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit11822010
CelcuityFor profit4432022
Big Ten Cancer Research ConsortiumAcademic/Hospital1012019
Curie InstituteAcademic/Hospital1112015
Eastchester Center for Cancer CareAcademic/Hospital1112016
Fondation ARCAcademic/Hospital1012015
Harvard UniversityAcademic/Hospital1112017
Indiana UniversityAcademic/Hospital1112018
National Cancer Institute, FranceGovernment1012015
Oncology Institute of Southern SwitzerlandAcademic/Hospital1112014
Ospedale S. Giovanni BellinzonaAcademic/Hospital1012014
Seoul National UniversityAcademic/Hospital1112018
Translational Breast Cancer Research Consortium (TBCRC)Academic/Hospital1012018
University of FloridaAcademic/Hospital1112017
University of PennsylvaniaAcademic/Hospital1112018
University of WisconsinAcademic/Hospital1112019
16 organizations
Page 1 / 1